A Phase II Study with 5-Fluorouracil, Folinic Acid and Oxaliplatin (FOLFOX-4 Regimen) in Patients with Metastatic Renal Cell Carcinoma
Authors:
- J. BennounaJBJ. Bennouna
- R. DelvaRDR. Delva
- F. GomezFGF. Gomez
- T. LesimpleTLT. Lesimple
- L. GeoffroisLGL. Geoffrois
- C. LinassierCLC. Linassier
- C. ChevreauCCC. Chevreau
- J.Y. DouillardJDJ.Y. Douillard
- S. NégrierSNS. Négrier
- 1 December 2002
- journal article
- clinical trial
- Published by S. Karger AG in Oncology
- Vol. 64 (1) , 25-27
Abstract
Purpose: To investigate the efficacy and safety of the FOLFOX-4 regimen for patients with metastatic renal cell carcinoma (MRCC). Patients and Methods: Fifty-nine patients (median age 59 years) pre-treated or not by cytokines (29 vs. 30) received the FOLFOX-4 regimen every 2 weeks. Results: Three minor responses, and no complete or partial responses were obtained. The median progression-free survival was 3 months (95% CI: 2.6–3.4), the median survival 10.6 months (95% CI: 8.7–12.4), with no difference between pre-treated patients and others. Treatment was well tolerated. Conclusion: The FOLFOX-4 regimen is ineffective in patients with MRCC. We believe that oxaliplatin should no longer be explored in renal carcinoma.Keywords
This publication has 5 references indexed in Scilit:
- Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell TransplantationNew England Journal of Medicine, 2000
- Oxaliplatin, 5-Fluorouracil, and Folinic Acid (Folfox) in Patients With Metastatic Renal Cell CarcinomaAmerican Journal of Clinical Oncology, 2000
- Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybridsNature Medicine, 2000
- Kidney cancerThe Lancet, 1998
- Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 1998